Arvinas, Inc. ARVN 深 滬
等待開盤 06-25 09:30:00 美东时间
8.05
-0.090
-1.11%
華盛通- 最 高8.48
- 今 開7.995
- 成交量 67.72万股
- 最 低 7.97
- 昨 收 8.14
- 總市值 5.19亿
- 52周最高 14.51
- 市盈率 靜 --
- 換手率 1.05%
- 52周最低 6.055
- 委 比 38.37%
- 總股本 6452.12万
- 歷史最高 108.465
- 量 比 0.92
- 振 幅 6.27%
- 歷史最低 5.90
- 每 手 1
- 風險率 2.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元
火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>
06-04 11:36
Arvinas Announces Re-Prioritization Of Portfolio Following Strategic Review; Plans To Complete Phase 1 Monotherapy Dose Escalation Trial And Share Data In 2026; Plans To Seek Out-Licensing Agreement For Additional Clinical Trials Of ARV-806; Expects Cash Position As Of March 31, 2026 To Fund Operations Into Second Half Of 2028
Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its portfolio. As previously disclosed, in the second quarter of 2026, the Company announced that it had completed dose
06-03 04:47
Full Transcript: Arvinas Q1 2026 Earnings Call
Arvinas (NASDAQ:ARVN) reported first-quarter financial results on Tuesday. The ...
06-01 19:55
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
BTIG Maintains Buy on Arvinas, Raises Price Target to $18
BTIG analyst Jeet Mukherjee maintains Arvinas (NASDAQ:ARVN) with a Buy and raises the price target from $16 to $18.
05-13 19:15
Arvinas, Pfizer Strike Up To $405M VEPPANU Licensing Deal With Rigel
Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE:PFE) have entered into a license agreement with Rigel Pharmaceuticals, Inc.,
05-12 19:21
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Arvinas Q1 EPS $(0.90) Misses $(0.87) Estimate, Sales $15.600M Miss $18.097M Estimate
Arvinas (NASDAQ:ARVN) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.87) by 3.45 percent. This is a 178.95 percent decrease over earnings of $1.14 per share from the
05-12 19:08
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
Arvinas Receives FDA Approval For VEPPANU To Treat Adults With Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor-Mutated Advanced Or Metastatic Breast Cancer
Arvinas, Inc. (NASDAQ:ARVN), today with its partner Pfizer Inc. (NYSE:PFE), announced that the U.S. Food and Drug Administration (FDA) has granted approval for VEPPANU (vepdegestrant) for the treatment of adults with
05-02 00:47
